MedTrace Logo

A Study Of New Medicine (GSK 372475) For The Treatment Of Depression

NCT00448058 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 396

Last updated 2014-10-10

No results posted yet for this study

Summary

To evaluate the efficacy, safety, and tolerability of GSK372475 compared with placebo in the treatment of outpatient subjects with Major Depressive Disorder (MDD)

Conditions

  • Depressive Disorder

Interventions

DRUG

GSK372475

daily administration during the 10-week treatment phase

DRUG

venlafaxine

daily administration during the 10-week treatment phase

DRUG

placebo

daily administration during the 10-week treatment phase

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • Australia
  • Belgium
  • Bulgaria
  • Canada
  • Estonia
  • Finland
  • France
  • Germany
  • India
  • Poland
  • Slovakia
  • South Africa

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00448058 on ClinicalTrials.gov